A drug combination extends survival in refractory lung cancer patients

Scientists have identified a drug combination, when used in advanced lung cancer patients, shows a survival advantage in patients who no longer respond to existing therapies. They found that bexarotene and erlotinib can each repress the critical cell cycle regulator: cyclin D1. The drug combination also broadened the reach to include a specific subset of patients, such as those resistant due to the presence of a ras mutation in their cancer. The study was published in the June issue of Cancer Prevention Research.

Read the whole article on Physorg

More from Physorg